

Evaluation and Management of Strictures in PSC Using ERCP

**Raj J. Shah, M.D., FASGE, AGAF
Associate Professor of Medicine**

**University of Colorado School of Medicine
Medical Co-Director, Digestive Health Center
Director, Pancreaticobiliary Services**


University of Colorado Anschutz Medical Campus






Ernest "Mooney" Warther
Master Carver
Dover, Ohio

MRCP to Diagnose PSC



Endoscopic Retrograde Cholangiopancreatography (ERCP)



When to Perform ERCP

- **Confirm PSC**
- **Treat symptoms of cholestasis**
- **Exclude malignancy**
 - **Decompensation of known PSC**
 - ◆ **Worsening cholestasis**
 - ◆ **H/O variceal bleeding**
 - ◆ **Increasing cholangitis episodes**
 - ◆ **Elevated tumor serology or signs/symptoms of occult malignancy**

Dominant Stenoses

- Noted in 10% - 20% of PSC patients
- Main duct and/or right and left hepatic duct
 - Tissue sampling (brush and biopsy) to **exclude malignancy**
- Palliative treatment with balloon dilation and stenting
 - No RCT on optimal duration of dilation and/or stenting

**ERCP is Used to Treat
Symptoms and Exclude
Cancer**

Treatment Options

- ERCP with passage or balloon dilation alone
- ERCP with dilation followed by stenting
 - ◆ U of Colorado preference – similar strategy as multiple stents for benign post-choly strictures
- PTC with drainage tubes – for ERCP failures
- Antibiotic prophylaxis


Extrahepatic PSC



Extrahepatic PSC



After two endotherapy sessions




Intrahepatic PSC



Intrahepatic PSC








Pre-Stenting



Post-Stenting




ERCP Tissue Sampling in PSC


- **Brush cytology:**
 - **Sensitivity: 29-73%**
 - **Specificity: 95%-100%**
- **Biopsy forceps:**
 - **Sensitivity: 29%**
 - **Specificity: 100%**

Fluorescence in situ hybridization (FISH)


- Four fluorescently labeled probes that hybridize to pericentric regions
 - Cs 3, 7, 17, 9p21
 - Fluorescence microscope

Figure 3. Cells from fluorescence in situ hybridization (FISH) specimens representing: (A) disomy (2 signals for each of the 4 probes), (B) trisomy 7 (3 signals representing chromosome 7 and 2 signals for the other probes), and (C) polysomy (≥ 3 signals for ≥ 2 probes). CEP 3 (red), CEP 7 (green), CEP 17 (aqua), LSI 9p21 (gold).






Biliary Probe-based Confocal Laser Endomicroscopy (pCLE)



3F Laser Fiber



A histological section of tissue stained with hematoxylin and eosin (H&E). The image shows a dense cellular structure with various glandular and ductal formations. A grey text box with a yellow border is overlaid on the left side of the image. Two yellow arrows point from the text box towards the right side of the image, highlighting specific areas of the tissue.

Field of View – 325 μcm (greater than one-fourth mm)
Lateral resolution of 3.5 μcm
Visualization depth - 40-70 micrometer

Measures of Validity for pCLE in PSC Patients with Dominant Stenoses

| Operating Characteristics | pCLE % (CI%) | Tissue Sampling % (CI%) |
|---------------------------|-----------------|-------------------------|
| Sensitivity | 100 (19-100) | 0 (0 - 81) |
| Specificity | 61 (36-83) | 94 (73-99) |
| NPV | 100 (71-100) | 90 (67 - 98) |
| PPV | 22 (4-60) | 0 (0-84) |

** Two explants – corresponding dysplasia (LGD and HGD) suspected by pCLE not confirmed by ERCP sampling

Multicenter Registry Study of pCLE in PSC Patients with Dominant Stenoses

Participating Centers:

U of Colorado


U of Pittsburgh

Cornell, NYC


Columbia, NYC

PSC Patient 3 (liver transplant)

- 58 year-old male
- PSC for 15+ years, UC for 20+ years
- Indication- Suspected hilar mass on CT and rising CA19-9 (169)




Cellvizio



20 µm


Cellvizio



20 µm


PSC Patient 3 (liver transplant)

- Liver explant showed benign changes!



PSC Patient 8

- 19 year-old male
- ≤ 1 year of PSC and UC
- Indication for pCLE – brushings from DS with highly atypical ductal cells suspicious for carcinoma. CA19-9 (9.3)



Stricture at common bile duct
Pathology- biopsy HGD and FISH showed
polysomy
Follow-up ERCP showed HGD in distal CBD and
right main duct.
Awaiting Transplant

Conclusions

- **Lab studies, imaging such as CT or MRI, and symptoms will determine need for ERCP**
- **ERCP is used to evaluate and treat dominant stenoses**
- **Dominant stenoses are narrowings in the main trunk of the tree (common bile duct) or its main branches**
- **Biopsies and brushings are done to help to exclude cancer.**
- **Laser confocal microscopy is promising to further evaluate strictures in PSC**

Evaluation and Management of Strictures in PSC Using ERCP

**Raj J. Shah, M.D., FASGE, AGAF
Associate Professor of Medicine**

**University of Colorado School of Medicine
Medical Co-Director, Digestive Health Center**

**Director, Pancreaticobiliary Services
University of Colorado Anschutz Medical Campus**

